This content is in French.
Vaccine vs. SMC: rivals or partners?
24 avril 2025
#MalariaVaccine #R21MatrixM #Malaria #Vaccination #SMC #InsecticideTreatedNets
#Immunization #VaccineAcceptability
Despite decades of efforts, malaria remains a major health threat to populations in sub-Saharan Africa. In 2022, the World Health Organization estimated 233 million cases on the continent, resulting in 580,000 deaths. Far from receding, the disease is showing a worrying resurgence, fueled by therapy resistance and the limitations of health systems.
Despite decades of efforts, malaria remains a major health threat to populations in sub-Saharan Africa. In 2022, the World Health Organization estimated 233 million cases on the continent, resulting in 580,000 deaths. Far from receding, the disease is showing a worrying resurgence, fueled by therapy resistance and the limitations of health systems.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Diawara, H., et al. (2025). Acceptability of the R21/Matrix-M malaria vaccine alongside existing malaria interventions in the trial context. BMJ global health, 10(2), e015524
View the source
